In this meta-analysis, we demonstrated that the use of SGLT2 inhibitors is associated with a lower risk of AF recurrence after an index catheter ablation in an adult population, an effect that persisted up to 18 months of follow-up. The gene discussed is SLC5A2; the disease is atrial fibrillation.